Merck KGaA MRK.DE
Composite 52/100; the shares have moved about 28% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 29/100 — a moderate mark against it.
Momentum ranks 72/100 — a moderate point in its favour. Balance-sheet strength ranks 60/100 — a slight point in its favour. Income ranks 52/100 — a slight point in its favour.
Growth ranks 29/100 — a moderate mark against it. Valuation ranks 44/100 — a slight mark against it.
What the company does Merck KGaA operates in three segments: Life Science (lab products and bioprocessing), Healthcare (prescription drugs in oncology, rare diseases, and immunology), and Electronics (advanced materials). Its Life Science unit supplies tools for research, production, and testing, while Healthcare focuses on high-margin specialty pharmaceuticals.
Key financials Merck KGaA reports gross margins of 58.9% and net margins of 12.1%, with ROE at 8.5% and ROA at 4.7%. Revenue declined -2.8% and EPS fell -10.1%, while debt/equity stands at 0.40 and interest coverage is 8.49. Forward P/E is 20.79, EV/EBITDA is 11.74, and FCF yield is 5.0%.
Stock health The stock shows strong momentum with 3m/6m/12m gains of 31.85%, 17.61%, and 32.98%, respectively. RSI(14) is 64.70, and the current ratio is 1.51. Strength pillar scores 70.0, while growth lags at 28.8.
Price vs fair value The stock trades at a **PREMIUM of 58.10%** to our fair-value estimate of 60.74 and a **discount of 0.82%** to the 12-month target of 146.29. - Fair-value gap widens amid sector-wide pipeline concerns (Sanofi CEO signals challenges, WSJ 2026-07-30). - Analysts (n=14) price target implies limited upside, suggesting near-term valuation constraints. - Strong momentum (RSI 64.70) may justify premium despite weak growth metrics.
Looking forward Forward P/E of 20.79 and PEG of 1.09 suggest moderate valuation relative to growth, but revenue/EPS declines (-2.8%/-10.1%) remain a concern. Life Science and Electronics segments may drive stability, while Healthcare’s specialty drugs could support margins. Monitor pipeline progress and margin trends.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.